Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G for Viridian Therapeutics, Inc. Common Stock, $0.01 par value per share (VRDN).
- Disclosed ownership: 5.3%.
- Date of event: 04 Apr 2025.
Commodore Capital LP - 04 Apr 2025 SCHEDULE 13G Report for Viridian Therapeutics, Inc. Common Stock, $0.01 par value per share (VRDN)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- VRDN
- Shares outstanding
- 81,132,075 shares
- Disclosed Ownership
- 4,300,000 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G
- Filing time
- 11 Apr 2025, 17:15:04 UTC
- Date of event
- 04 Apr 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 5.3% ownership in Viridian Therapeutics, Inc. Common Stock, $0.01 par value per share (VRDN) on 04 Apr 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 11 Apr 2025, 17:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 5.3% | 4,300,000 | 0 | 4,300,000 | /s/ Michael Kramarz | Michael Kramarz, Managing Partner | |
| Commodore Capital Master LP | 5.3% | 4,300,000 | 0 | 4,300,000 | /s/ Michael Kramarz | Michael Kramarz, Authorized Signatory |